Neurocrine Biosciences (NBIX) Operating Income Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) Operating Income Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.42 Bn | 87.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn | 273.62% |
| 3 | Zoetis | 32.44 Bn | 30.50 Bn | 1.62 Bn | 3.84% |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn | -59.82% |
| 5 | United Therapeutics | 23.13 Bn | 20.98 Bn | 648.10 Mn | 4.63% |
| 6 | RedHill Biopharma | 21.17 Bn | 21.17 Bn | - | - |
| 7 | Viatris | 20.33 Bn | 18.53 Bn | 1.16 Bn | -30.05% |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.45 Bn | 800.70 Mn | 54.58% |
| 9 | Elanco Animal Health | 12.63 Bn | 12.20 Bn | 785.00 Mn | 40.17% |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | 190.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 54.58% |
| Dec 31, 2025 | 26.82% |
| Sep 30, 2025 | 39.63% |
| Jun 30, 2025 | 38.59% |
| Mar 31, 2025 | 96.72% |
| Dec 31, 2024 | 80.82% |
| Sep 30, 2024 | 60.45% |
| Jun 30, 2024 | 32.29% |
| Mar 31, 2024 | 46.63% |
| Dec 31, 2023 | 27.92% |
| Sep 30, 2023 | 73.11% |
| Jun 30, 2023 | -1.32% |
| Mar 31, 2023 | -57.93% |
| Dec 31, 2022 | 28.44% |
| Sep 30, 2022 | -0.86% |
| Jun 30, 2022 | 16.72% |
| Mar 31, 2022 | 26.63% |
| Dec 31, 2021 | -54.21% |
| Sep 30, 2021 | -6.43% |
| Jun 30, 2021 | 229.92% |